Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries

Bulletin of the World Health Organization

Volumn 92, Issue 9, 2014, Pages 630-640

  Leopold, Christine ^a   Mantel Teeuwisse, Aukje K ^b   Vogler, Sabine ^a   Valkova, Silvia ^c   de Joncheere, Kees ^d   Leufkens, Hubert G M ^b   Wagner, Anita K ^e   Ross Degnan, Dennis ^e   Laing, Richard ^d  

^a GESUNDHEIT ÖSTERREICH GMBH   (Austria)

^b UTRECHT UNIVERSITY   (Netherlands)

^c IMS Institute for Healthcare Informatics   (United States)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMMERCIAL PHENOMENA; DRUG CONTROL; DRUG COST; ECONOMIC RECESSION; ECONOMICS; EUROPE; HUMAN; STATISTICS AND NUMERICAL DATA;

COMMERCE; DRUG AND NARCOTIC CONTROL; DRUG COSTS; ECONOMIC RECESSION; EUROPE; HUMANS;

EID: 84906894968     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.13.129114     Document Type: Article

References (44)

1. Habl C, Antony K, Entleitner M, Fröschl B, Leopold C, Stürzlinger H, et al. Surveying, assessing and analyzing the pharmaceutical sector in the 25 EU Member States. Luxembourg: European Communities; 2006. Available from: http://ec.europa.eu/competition/mergers/studies_reports/oebig.pdf [cited 2014 May 7].
2. Mossialos E, Mrazek M, Walley T. Regulating pharmaceuticals in Europe: striving for efficiency, equity, and quality. European Observatory on Health Care Systems series. Maidenhead: Open University Press; 2004.
3. Docteur E, Paris V. Pharmaceutical pricing policies in a global market. Paris: The Organization for Economic Co-operation and Development; 2008.
4. Seiter A. Access to medicines and the innovation dilemma - Can pharmaceutical multinationals be good corporate citizens? Bus Ethics Innov Ethics Sci Technol Assess. 2007;31:89-100. doi: http://dx.doi.org/10.1007/978-3-540-72310-3_6
5. Shelburne R, Trentini C. Public health in Europe: the 2007-2009 financial crisis and UNECE activities. Discussion paper series No. 2009.2. Geneva: United Nations Economic Commission for Europe; 2009. Available from: http://www.unece.org/fleadmin/DAM/oes/disc_papers/ECE_DP_2009-2.pdf [cited 2013 Feb 10].
6. The economic situation in 2008-2009 in the Economic Commission for Europe region: Europe, North America and the Commonwealth of Independent States. Geneva: United Nations Economic and Social Council; 2009. Available from: http://daccess-dds-ny.un.org/doc/UNDOC/GEN/N09/331/44/PDF/N0933144.pdf?OpenElement [cited 2014 May 07].
7. Schrader K, Laaser CF. Die Krise in Südeuropa oder die Angst vor dem Dominoefekt. Griechenland, Portugal und Spanien im Krisentest. Kiel: Institut für Weltwirtschaft; 2012. German. Available from: http://www. ifw-kiel.de/pub/kd/2012/kd500-501.pdf [cited 2014 May 7].
8. Averting a human crisis during the global downturn: policy options from the World Bank's Human Development Network. Washington: World Bank; 2009. Available from: http://siteresources.worldbank.org/NEWS/Resources/AvertingTheHumanCrisis.pdf [cited 2014 May 7].
9. Stuckler D, Basu S, Suhrcke M, Coutts A, McKee M. The public health effect of economic crises and alternative policy responses in Europe: an empirical analysis. Lancet. 2009;374(9686):315-323. doi: http://dx.doi.org/10.1016/S0140-6736(09)61124-7 PMID: 19589588
10. Holahan J. The 2007-09 recession and health insurance coverage. Health Af (Millwood). 2011;30(1):145-52. doi: http://dx.doi.org/10.1377/hlthaf.2010.1003 PMID: 21134911
11. Lusardi A, Schneider D, Tufano P. The economic crisis and medical care usage. National Bureau of Economic Research Working Paper. Hanover: Dartmouth College; 2010. Available from: http://www.dartmouth.edu/~alusardi/Papers/healthcare_031610.pdf [cited 2014 May 7].
12. Fronstin P. The impact of the recession on employment-based health coverage. EBRI Issue Brief. 2010;342(342):1-22. PMID: 20578430
13. Trufer CJ, Keehan S, Smith S, Cylus J, Sisko A, Poisal JA, et al. Health spending projections through 2019: the recession's impact continues. Health Af (Millwood). 2010;29(3):522-9. doi: http://dx.doi.org/10.1377/hlthaf.2009.1074 PMID: 20133357
14. McKee M, Stuckler D, Martin-Moreno JM. Protecting health in hard times. BMJ. 2010;341:c5308. doi: http://dx.doi.org/10.1136/bmj.c5308 PMID: 20880907
15. Kentikelenis A, Karanikolos M, Papanicolas I, Basu S, McKee M, Stuckler D. Health effects of financial crisis: omens of a Greek tragedy. Lancet. 2011;378(9801):1457-1458. doi: http://dx.doi.org/10.1016/S0140-6736(11)61556-0 PMID: 21988763
16. Buysse IM, Laing RO, Mantel-Teeuwisse AK. Impact of the economic recession on the pharmaceutical sector [Internet]. Geneva: World Health Organization; 2010. Available from: http://apps.who.int/medicinedocs/en/m/abstract/Js17419e/ [cited 2013 Feb 10].
17. Vogler S, Zimmermann N, Leopold C, de Joncheere K. Pharmaceutical policies in European countries in response to the global fnancial crisis. South Med Rev. 2011;4(2):69-79. doi: http://dx.doi.org/10.5655/smr.v4i2.1004 PMID: 23093885
18. de Belvis AG, Ferrè F, Specchia ML, Valerio L, Fattore G, Ricciardi W. The financial crisis in Italy: implications for the healthcare sector. Health Policy. 2012;106(1):10-6. doi: http://dx.doi.org/10.1016/j.healthpol.2012.04.003 PMID: 22551787
19. Glossary of pharmaceutical terms. Update 2013. Vienna: World Health Organization Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies; 2013. Available from: http://whocc.goeg.at/Literaturliste/Dokumente/MethodologyTemplate/PHIS%20Glossary_ Update2013_fnal_gesamt.pdf [cited 2014 Apr 30].
20. Anatomical classification [Internet]. London: European Pharmaceutical Market Research Association; 2014. Available from: http://www.ephmra.org/Anatomical-Classification [cited 2014 Apr 30].
21. Restoring public finances, 2012 update [Internet]. Paris: Organization for Economic Co-operation and Development; 2012. Available from: http://www.oecd.org/gov/budgeting/restoringpublicfnances-reportoutliningthefiscalconsolidationplansof30oecdcountries.htm [cited 2014 May 7].
22. OECD. Stat Extracts. Health. Demographic references [Internet]. Paris: Organisation for Economic Co-operation and Development; 2013. Available from: http://stats.oecd.org/ [cited 2014 May 7].
23. Marmot MG, Bell R. How will the financial crisis affect health? BMJ. 2009;338:b1314. doi: http://dx.doi.org/10.1136/bmj.b1314 PMID: 19359306
24. Leyland AH. Alcohol, financial crisis and reform: learning from the Russian experience. Eur J Public Health. 2012;22(3):300. doi: http://dx.doi.org/10.1093/eurpub/cks051 PMID: 22556037
25. Polyzos N. Health and the financial crisis in Greece - author's reply. Lancet. 2012;379(9820):1002. doi: http://dx.doi.org/10.1016/S0140-6736(12)60421-8 PMID: 22423876
26. Yang BM, Prescott N, Bae EY. The impact of economic crisis on health-care consumption in Korea. Health Policy Plan. 2001;16(4):372-85. doi: http://dx.doi.org/10.1093/heapol/16.4.372 PMID: 11739362
27. Parry J, Humphreys G. Health amid a financial crisis: a complex diagnosis. Bull World Health Organ. 2009;87(1):4-5. doi: http://dx.doi.org/10.2471/BLT.09.010109 PMID: 19197395
28. Catalano R. Health, medical care, and economic crisis. N Engl J Med. 2009;360(8):749-51. doi: http://dx.doi.org/10.1056/NEJMp0809122 PMID: 19228617
29. Navarro V. The crisis and fiscal policies in the peripheral countries of the Eurozone. Int J Health Serv. 2012;42(1):1-7. doi: http://dx.doi.org/10.2190/HS.42.1.a PMID: 22403904
30. Ornelas A. Recession-hit nations owe pharma firms billions [Internet]. Bern: Swissinfo.ch; 2012. Available from: http://www.swissinfo.ch/eng/business/Recession-hit_nations_owe_pharma_frms_billions.html?cid=32185254 [cited 2013 Jul 10].
31. PGEU statement on medicine shortages in European Community pharmacies [Internet]. Brussels: Pharmaceutical Group of European Union; 2013. Available from: http://www.pgeu.eu/en/library/2-position-papers/154-pgeu-statement-on-medicine-shortages-in-european-community-pharmacies.html [cited 2013 Jun 10].
32. Harmonised Indices of Consumer Prices (HICPs) - inflation rate. Annual average rate of change (%) 2006-2013 [Internet]. Brussels: EUROSTAT; 2013. Available from: http://epp.eurostat.ec.europa.eu/tgm/table.do?tab=table&plugin=1&language=en&pcode=tec00118 [cited 2014 Jan 20].
33. Economic slowdown shaping healthcare system [Internet]. Gütersloh: Health Policy Monitor; 2009. Available from: http://hpm.org/en/Surveys/PRAXIS_Estonia/13/Economic_slowdown_shaping_healthcare_system.html [cited 2014 May 7].
34. Leopold C, Vogler S, Bucsics A. Aktuelle Heilmittelausgaben und arzneimittelpolitische Trends in Europa. Soziale Sicherheit. 2013;9:414-429. German.
35. Kanavos P, Nicod E, Espin J, van den Aardweg S. Short- and long-term effects of value-based pricing vs. external price referencing. Brussels: Directorate-General for Enterprise and Industry; 2010. Available from: http://ec.europa.eu/enterprise/sectors/healthcare/fles/docs/valuebased_pharmapricing_012010_en.pdf [cited 2014 May 7].
36. Husereau D, Cameron C. Value-based pricing of pharmaceuticals in Canada: opportunities to expand the role of health technology assessment? CHSRF series of reports on cost drivers and health systems efficiency: Paper 5 [Internet]. Ottawa: Canadian Foundation for Healthcare Improvement; 2011. Available from: http://www.cfhi-fcass.ca/SearchResultsNews/11-12-16/8eeaf655-b2b6-4c39-a909-6854acfea850.aspx [cited 2014 May 7].
37. Espín J, Rovira J, García L. Experiences and impact of European risk-sharing schemes focusing on oncology medicines. Brussels: Directorate-General for Enterprise and Industry; 2011. Available from: http://ec.europa.eu/enterprise/sectors/healthcare/fles/docs/risksharing_oncology_012011_ en.pdf [cited 2014 May 7].
38. Kanavos P., Ferrario A. Managed entry agreements for pharmaceuticals: the European experience. Brussels: Directorate-General for Enterprise and Industry; 2013. Available from: http://ec.europa.eu/enterprise/sectors/healthcare/fles/docs/mea_report_en.pdf [cited 2014 May 7].
39. Pohjolainen L. Reference price and price competition - evidence from the Finnish pharmaceutical market [thesis]. Helsinki: Aalto University; 2012. Available from: https://aaltodoc.aalto.f/handle/123456789/3456 [cited 2012 Aug 20].
40. Habl C, Vogler S, Leopold C, Schmickl B, Fröschl B. Referenzpreissysteme in Europa. Analyse und Umsetzungsvoraussetzungen für Österreich. Vienna: ÖBIG Forschungs- und Planungsgesellschaft mbH; 2008. German.
41. Wladysiuk M, Araszkiewicz A, Godman B, Szabert K, Barbui C, Haycox A. Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are available. Appl Health Econ Health Policy. 2011;9(2):101-10. doi: http://dx.doi.org/10.2165/11318840-000000000-00000 PMID: 21271749
42. Andersson K, Petzold MG, Sonesson C, Lönnroth K, Carlsten A. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002. Health Policy. 2006;79(2-3):231-43. doi: http://dx.doi.org/10.1016/j.healthpol.2006.01.007 PMID: 16473436
43. Soumerai SB, Zhang F, Ross-Degnan D, Ball DE, LeCates RF, Law MR, et al. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Af (Millwood). 2008;27(3):w185-95. doi: http://dx.doi.org/10.1377/hlthaf.27.3.w185 PMID: 18381404
44. Ong M, Catalano R, Hartig T. A time-series analysis of the effect of increased copayments on the prescription of antidepressants, anxiolytics, and sedatives in Sweden from 1990 to 1999. Clin Ther. 2003;25(4):1262-75. doi: http://dx.doi.org/10.1016/S0149-2918(03)80082-6 PMID: 12809972